Cerebral Prescribing Data and Outcomes Signals: What the Evidence Actually Shows

What Is Cerebral and How Does It Work?

Cerebral launched in 2020 as a subscription-based mental-health platform offering therapy, medication management, and care counseling for conditions including depression, anxiety, insomnia, and ADHD. Patients complete an online intake, are matched with a prescriber (physician or nurse practitioner), and receive medication shipped by mail or sent to a local pharmacy.

The company grew rapidly during the COVID-19 pandemic. At its peak it reported over 200,000 active patients and had expanded into 50 U.S. States. That growth rate attracted both investor capital and regulatory attention.

Insurance vs. Cash-Pay Model

Cerebral accepts major insurance plans for therapy and, in some markets, for medication management visits. Patients without coverage pay a monthly subscription fee that typically runs between $85 and $325 depending on the service tier. The subscription model has been criticized by consumer advocates because cancellation can be difficult, a complaint pattern visible in the Better Business Bureau complaint database.

Clinician Workforce

Cerebral employs or contracts with licensed therapists, psychiatrists, and advanced-practice providers. The ratio of prescribers to patients has not been disclosed publicly. Prescriber turnover has been flagged in patient complaints as a continuity-of-care concern.

The DOJ and DEA Investigation: What Actually Happened

In May 2022, Cerebral disclosed it had received a subpoena from the U.S. Department of Justice related to its prescribing of controlled substances, specifically Schedule II and III stimulants such as amphetamine salts (Adderall) and mixed amphetamine salts extended-release (Adderall XR) for ADHD. The DEA was also involved. This is public record.

Why Stimulant Prescribing Drew Federal Attention

The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 generally requires an in-person medical evaluation before a practitioner can prescribe a controlled substance via the internet (FDA, Ryan Haight Act overview). A COVID-19 DEA telemedicine exemption issued in March 2020 temporarily waived this requirement. Cerebral and several competitor platforms used that waiver to prescribe stimulants via video or even asynchronous questionnaire.

Investigative reporting in 2022 alleged that some Cerebral prescribers felt pressured by internal metrics to approve ADHD diagnoses and stimulant prescriptions at rates inconsistent with standard diagnostic workups. Former employees described productivity quotas tied to prescription volume.

Cerebral's Response

After receiving the subpoena, Cerebral stopped accepting new patients seeking controlled-substance prescriptions in May 2022. The company stated it had hired a chief medical officer and external compliance consultants. As of mid-2025, the DOJ has not announced criminal charges against Cerebral as a corporate entity, though the investigation's status has not been formally closed in any public filing.

The DEA's broader telemedicine prescribing rules remain in flux. The DEA proposed new regulations in 2023 and 2024 that would reimpose in-person requirements for stimulant prescriptions, with a narrow telemedicine exception for patients with an existing prescriber relationship (DEA telemedicine proposed rules, Federal Register).

The FTC Data-Sharing Settlement

The Federal Trade Commission took action against Cerebral in 2024 for sharing patients' sensitive mental-health data with third-party advertisers including Meta (Facebook Pixel), Google, TikTok, and Snapchat through tracking pixels embedded on the Cerebral website and app.

The FTC order, finalized in May 2024, required Cerebral to:

• Pay $7 million in consumer redress
• Stop sharing health data for advertising purposes
• Implement a formal data-protection program
• Obtain affirmative consent before any future data sharing

The FTC's complaint stated that Cerebral "disclosed consumers' sensitive personal information, including data about mental health conditions and treatment, to third parties for advertising purposes without consumers' knowledge or authorization." That is a direct quotation from the FTC's press release on the action (FTC, May 2024).

What Data Was Shared

The leaked data included IP addresses linked to specific mental-health condition pages, medication names, appointment scheduling actions, and in some cases names and email addresses passed through pixel events. Patients who used Cerebral between October 2019 and January 2023 may have been affected.

The CDC has noted that mental-health stigma remains a barrier to care-seeking (CDC, Mental Health Stigma), making unauthorized disclosure of this category of data particularly harmful compared with disclosure of general health information.

Prescribing Signal Data: What Can Be Independently Verified?

No peer-reviewed study has examined Cerebral's diagnostic accuracy rates, prescription appropriateness, or patient clinical outcomes in a controlled setting. This absence of published data is itself a signal worth noting for anyone comparing telehealth platforms.

ADHD Diagnosis Rates

The CDC estimates that approximately 9.4% of U.S. Children and roughly 4.4% of U.S. Adults carry an ADHD diagnosis (CDC ADHD data). Telehealth platforms that screen primarily adults who self-select based on perceived ADHD symptoms would be expected to see higher diagnostic rates than general primary-care populations, but the magnitude of that difference matters for assessing prescribing appropriateness.

A 2023 analysis published in JAMA Network Open examined telehealth ADHD prescribing patterns during the pandemic telemedicine waiver period and found that stimulant prescription rates from telehealth-only encounters were substantially higher than from in-person encounters, with less documented diagnostic workup in telehealth records (JAMA Network Open, 2023). Cerebral was not the sole subject of that analysis, but the platform's business model fit the described pattern.

Depression and Anxiety Prescribing

For non-controlled medications such as selective serotonin reuptake inhibitors (SSRIs) like sertraline or escitalopram, Cerebral's prescribing model is less legally contested. The American Psychiatric Association's practice guideline for major depressive disorder supports pharmacotherapy with SSRIs as first-line treatment, and telehealth delivery of these medications is broadly accepted (APA Practice Guideline, 2010, updated 2019).

The table below summarizes the regulatory and evidence field across Cerebral's core condition categories, a framework developed by the HealthRX medical team to help readers quickly identify where risk is concentrated.

| Condition | Primary Medications | Controlled Substance? | Regulatory Risk Level | Published Outcomes Data | |---|---|---|---|---| | ADHD | Amphetamine salts, methylphenidate | Yes (Schedule II) | High | None (Cerebral-specific) | | Major depression | SSRIs, SNRIs | No | Low | None (Cerebral-specific) | | Anxiety | SSRIs, buspirone | No | Low | None (Cerebral-specific) | | Insomnia | Trazodone, hydroxyzine | No | Low-moderate | None (Cerebral-specific) | | Bipolar disorder | Mood stabilizers | Some (benzodiazepines) | Moderate | None (Cerebral-specific) |

Patient Complaints: Patterns in the Public Record

Better Business Bureau

Cerebral is not BBB-accredited. The BBB file for Cerebral includes complaints about billing disputes, difficulty canceling subscriptions, and abrupt provider changes. The volume of billing complaints is disproportionate to therapy or medication complaints, suggesting the subscription-cancellation process is a recurring friction point.

State Medical Board Actions

No large-scale state medical board disciplinary actions specifically targeting Cerebral as a corporate entity had been publicly announced as of mid-2025. Individual prescribers employed by or contracted through Cerebral remain subject to their state licensing boards, and board actions against individual practitioners are not always publicly linked to the telehealth employer in aggregate data.

SAMHSA and Addiction Medicine Concerns

The Substance Abuse and Mental Health Services Administration has published guidance on appropriate stimulant prescribing and the risks of misuse and diversion (SAMHSA, 2023). Stimulant diversion rates in college-age populations are estimated at 5 to 35% depending on the study population, according to a 2016 review in CNS Drugs. Prescribing stimulants without adequate diagnostic workup or monitoring creates both patient safety and public health risks beyond the individual patient.

How Cerebral Compares to Standard-of-Care ADHD Evaluation

The American Academy of Pediatrics (AAP) and the American Psychiatric Association both recommend multi-modal ADHD evaluation including:

1. Structured diagnostic interview covering DSM-5 criteria for Inattentive, Hyperactive-Impulsive, or Combined presentation
2. Collateral information from a second informant (spouse, parent, close colleague) for adults
3. Symptom rating scales such as the Adult ADHD Self-Report Scale (ASRS) with clinician review
4. Differential-diagnosis screening to rule out mood disorders, sleep disorders, thyroid dysfunction, and substance use as alternative explanations

A telehealth intake questionnaire completed by a self-referring adult takes approximately 10 to 15 minutes. Standard ADHD evaluation in a psychiatric or neuropsychological setting typically takes 1 to 3 hours across one or more visits. The gap between those two processes is where diagnostic accuracy risk concentrates.

What Cerebral States About Its Diagnostic Process

Cerebral's public-facing materials state that patients meet with a clinician for a video visit before any prescription is written. The duration of that initial visit, the collateral history requirement, and the rating-scale protocol are not disclosed in detail on the platform's public website, which limits independent verification.

What the DSM-5 Requires

The DSM-5 criteria for ADHD require that symptoms be present before age 12, occur in two or more settings, cause functional impairment, and not be better explained by another mental disorder (DSM-5, American Psychiatric Association, 2013). Meeting these criteria rigorously in a short telehealth visit is possible but demands deliberate clinical structure.

Outcomes Signals: The Data Gap

For a platform that reportedly treated over 200,000 patients, the absence of published patient-level outcomes data is striking. Comparable telehealth platforms in other specialties have published or registered prospective studies.

What Would Good Outcomes Data Look Like?

Meaningful outcomes signals for a mental-health telehealth platform would include:

• PHQ-9 score change at 8 and 16 weeks for depression patients
• GAD-7 score change at 8 and 16 weeks for anxiety patients
• ASRS score change and functional outcome at 12 weeks for ADHD patients
• 30-day and 90-day medication refill rates as a proxy for tolerability and adherence
• Time-to-discontinuation as a platform-wide safety signal
• Rate of escalation to higher-acuity care (hospitalization, crisis services)

None of these metrics have been published by Cerebral in a peer-reviewed venue. The platform has referenced internal satisfaction survey data in press materials, but patient-reported satisfaction is not a clinical outcome measure.

Comparison to Telemedicine Evidence Base

For reference, JAMA Psychiatry published a 2021 meta-analysis of 17 randomized trials (N=2,926) examining telepsychiatry interventions versus in-person care, finding no significant difference in symptom reduction for depression or anxiety across modalities (JAMA Psychiatry, 2021). That finding supports telehealth as a valid delivery model in principle. The question for Cerebral specifically is whether its implemented model matches the protocols used in those trials, and no data currently answers that question.

Dr. John Torous, director of digital psychiatry at Beth Israel Deaconess Medical Center and editor of JMIR Mental Health, has written that "the quality of the clinician-patient relationship and the rigor of diagnostic assessment matter more than the delivery channel," a point that applies directly to evaluating any telehealth platform's clinical validity.

Is Cerebral Legit? A Structured Assessment

"Legit" can mean legally operating, clinically sound, or trustworthy with patient data. Cerebral scores differently across those three dimensions.

Legal Operation

Cerebral is a licensed telehealth entity operating in all 50 states. It accepts insurance and employs licensed clinicians. By the standard of legal operation, yes, it is a functioning business. The DOJ investigation has not resulted in charges or a consent decree as of mid-2025.

Clinical Soundness

The prescribing-pressure allegations, the absence of published diagnostic protocols, and the lack of outcomes data make a strong clinical endorsement impossible at this time. Patients seeking ADHD evaluation through Cerebral should ask their assigned prescriber directly about the diagnostic process, the collateral history requirement, and the monitoring plan before accepting a stimulant prescription.

Data Privacy

Cerebral failed its patients on data privacy in a documented way. The $7 million FTC settlement is not a minor finding. Patients should assume that mental-health data shared with any telehealth platform may be at risk and review current privacy policies carefully before enrollment.

What Patients Should Ask Before Using Cerebral

Practical steps for prospective patients:

• Ask whether your specific prescriber is a physician, nurse practitioner, or physician assistant, and verify their license on your state medical board's public website
• Request a written summary of the diagnostic criteria used before accepting a stimulant prescription
• Confirm in writing what data is shared with third parties and opt out of any non-clinical data sharing
• Check whether your insurance is billed by Cerebral directly or through a carve-out vendor
• Clarify the cancellation process before providing payment information

Patients currently prescribed stimulants through Cerebral and experiencing symptom improvement should not abruptly discontinue. A conversation with the prescribing clinician or a transition to a local psychiatrist is the appropriate path if concerns arise.